1. Home
  2. GPMT vs IPHA Comparison

GPMT vs IPHA Comparison

Compare GPMT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPMT
  • IPHA
  • Stock Information
  • Founded
  • GPMT 2015
  • IPHA 1999
  • Country
  • GPMT United States
  • IPHA France
  • Employees
  • GPMT N/A
  • IPHA N/A
  • Industry
  • GPMT Real Estate Investment Trusts
  • IPHA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPMT Real Estate
  • IPHA Health Care
  • Exchange
  • GPMT Nasdaq
  • IPHA Nasdaq
  • Market Cap
  • GPMT 148.4M
  • IPHA 148.3M
  • IPO Year
  • GPMT 2017
  • IPHA 2019
  • Fundamental
  • Price
  • GPMT $2.97
  • IPHA $1.77
  • Analyst Decision
  • GPMT Buy
  • IPHA Strong Buy
  • Analyst Count
  • GPMT 5
  • IPHA 1
  • Target Price
  • GPMT $4.58
  • IPHA $11.50
  • AVG Volume (30 Days)
  • GPMT 474.1K
  • IPHA 42.3K
  • Earning Date
  • GPMT 02-12-2025
  • IPHA 09-12-2024
  • Dividend Yield
  • GPMT 10.24%
  • IPHA N/A
  • EPS Growth
  • GPMT N/A
  • IPHA N/A
  • EPS
  • GPMT N/A
  • IPHA N/A
  • Revenue
  • GPMT N/A
  • IPHA $36,202,722.00
  • Revenue This Year
  • GPMT N/A
  • IPHA N/A
  • Revenue Next Year
  • GPMT $10.18
  • IPHA $101.65
  • P/E Ratio
  • GPMT N/A
  • IPHA N/A
  • Revenue Growth
  • GPMT N/A
  • IPHA N/A
  • 52 Week Low
  • GPMT $2.46
  • IPHA $1.29
  • 52 Week High
  • GPMT $6.13
  • IPHA $3.51
  • Technical
  • Relative Strength Index (RSI)
  • GPMT 51.42
  • IPHA 46.55
  • Support Level
  • GPMT $2.61
  • IPHA $1.65
  • Resistance Level
  • GPMT $3.01
  • IPHA $1.87
  • Average True Range (ATR)
  • GPMT 0.11
  • IPHA 0.12
  • MACD
  • GPMT 0.03
  • IPHA -0.03
  • Stochastic Oscillator
  • GPMT 90.00
  • IPHA 33.47

About GPMT Granite Point Mortgage Trust Inc.

Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning, and repurposing of the property.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Share on Social Networks: